Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (310)	1/1/1998 10:38:00 PM
From: John McCarthy	Read Replies (1) \| Respond to of 569

Jason - <<I thought drugs were orphaned for specific indications, such as Taxol for KS but not ovarian cancer.>> You are correct. Where I wrote ... <<In August the FDA ruled that TAXOL ($1 bil. drug) was indeed an ORPHAN DRUG.>> should read <<In August, the FDA ruled that TAXOL ($1 bil. drug) was indeed an ORPHAN DRUG for the K.S. indication.>> Having said that, my first writing, I think, is more accurate and goes to the heart of the matter. Regards, John McCarthy